Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina.
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer Epidemiol Biomarkers Prev. 2022 Jun 1;31(6):1176-1184. doi: 10.1158/1055-9965.EPI-21-1388.
There is a growing population of adolescent and young adult (AYA, age 15-39 years) acute leukemia survivors in whom long-term mortality outcomes are largely unknown.
The current study utilized the Surveillance, Epidemiology, and End Results (SEER) registry to assess long-term outcomes of AYA acute leukemia 5-year survivors. The impact of diagnosis age, sex, race/ethnicity, socioeconomic status, and decade of diagnosis on long-term survival were assessed utilizing an accelerated failure time model.
A total of 1,938 AYA acute lymphoblastic leukemia (ALL) and 2,350 AYA acute myeloid leukemia (AML) survivors diagnosed between 1980 and 2009 were included with a median follow-up of 12.3 and 12.7 years, respectively. Ten-year survival for ALL and AML survivors was 87% and 89%, respectively, and 99% for the general population. Survival for AYA leukemia survivors remained below that of the age-adjusted general population at up to 30 years of follow-up. Primary cancer mortality was the most common cause of death in early survivorship with noncancer causes of death becoming more prevalent in later decades of follow-up. Male AML survivors had significantly worse survival than females (survival time ratio: 0.61, 95% confidence interval: 0.45-0.82).
AYA leukemia survivors have higher mortality rates than the general population that persist for decades after diagnosis.
While there have been improvements in late mortality, long-term survival for AYA leukemia survivors remains below that of the general population. Studies investigating risk factors for mortality and disparities in late effects among long-term AYA leukemia survivors are needed.
患有青少年和年轻成人(AYA,年龄 15-39 岁)急性白血病的幸存者人数不断增加,其长期死亡率仍很大程度上未知。
本研究利用监测、流行病学和最终结果(SEER)登记处,评估 AYA 急性白血病 5 年幸存者的长期结局。利用加速失效时间模型评估诊断年龄、性别、种族/民族、社会经济地位和诊断年代对长期生存的影响。
共纳入 1980 年至 2009 年间诊断的 1938 例 AYA 急性淋巴细胞白血病(ALL)和 2350 例 AYA 急性髓细胞白血病(AML)幸存者,中位随访时间分别为 12.3 年和 12.7 年。ALL 和 AML 幸存者的 10 年生存率分别为 87%和 89%,普通人群为 99%。在长达 30 年的随访中,AYA 白血病幸存者的生存率仍低于年龄调整后的普通人群。癌症发病前死亡是早期生存中最常见的死亡原因,而非癌症原因的死亡在随访的后期几十年更为常见。AML 男性幸存者的生存状况明显差于女性(生存时间比:0.61,95%置信区间:0.45-0.82)。
AYA 白血病幸存者的死亡率高于普通人群,且在诊断后数十年仍持续存在。
尽管晚期死亡率有所改善,但 AYA 白血病幸存者的长期生存状况仍低于普通人群。需要研究死亡率的危险因素以及长期 AYA 白血病幸存者晚期效应的差异。